Immunic, Inc.(IMUX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMUX Immunic, Inc.

Trading 03-27 14:53:58 EDT

1.13

-0.13

-10.12%

High1.28	Low1.12	Vol2.27M
Open1.26	D1 Closing1.26	Amplitude12.50%
Mkt Cap147.75M	Tradable Cap108.49M	Total Shares130.46M
T/O2.65M	T/O Rate2.36%	Tradable Shares95.79M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMUX","market":"US","secType":"STK","nameCN":"Immunic, Inc.","latestPrice":1.1325,"timestamp":1774637638092,"preClose":1.26,"halted":0,"volume":2265220,"delay":0,"changeRate":-0.10119047619047615,"floatShares":95793500,"shares":130464800,"eps":-0.624145,"marketStatus":"Trading","change":-0.1275,"latestTime":"03-27 14:53:58 EDT","open":1.26,"high":1.28,"low":1.1225,"amount":2654325.90028,"amplitude":0.125,"askPrice":1.14,"askSize":9308,"bidPrice":1.13,"bidSize":2003,"shortable":0,"etf":0,"ttmEps":-0.624145,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774641600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1397707200000,"exchange":"NASDAQ","adjPreClose":1.26,"preHourTrading":{"tag":"盘前","latestPrice":1.2796,"preClose":1.26,"latestTime":"09:28 EDT","volume":16786,"amount":21478.6790526,"timestamp":1774618105040,"change":0.0196,"changeRate":0.015556,"amplitude":0.095238},"postHourTrading":{"tag":"盘后","latestPrice":1.2726,"preClose":1.26,"latestTime":"19:55 EDT","volume":8480,"amount":10768.1622,"timestamp":1774569348795,"change":0.0126,"changeRate":0.01,"amplitude":0.015873},"volumeRatio":1.373095,"impliedVol":0.9415,"impliedVolPercentile":0.2709},"requestUrl":"/m/hq/s/IMUX/wiki","defaultTab":"wiki","newsList":[{"id":"2621061272","title":"Guggenheim Initiates Coverage on Immunic With Buy Rating, $7 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061272","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061272?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:55","pubTimestamp":1774353305,"startTime":"0","endTime":"0","summary":"Immunic (IMUX) has an average rating of Buy and mean price target of $5.25, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMUX"],"gpt_icon":0},{"id":"2621061429","title":"Immunic Initiated at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2621061429","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621061429?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:49","pubTimestamp":1774352940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMUX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 07:49 ET (11:49 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"gpt_icon":0},{"id":"2621068884","title":"Immunic initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2621068884","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621068884?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:10","pubTimestamp":1774343420,"startTime":"0","endTime":"0","summary":"Guggenheim initiated coverage of Immunic (IMUX) with a Buy rating and $7 price target The company is advancing vidofludimus calcium, an oral multip...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunic-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunic-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMUX","BK4139"],"gpt_icon":0},{"id":"2619142820","title":"Should Extended European Patent Protection for Vidofludimus Calcium Reshape Immunic’s (IMUX) Long-Term Value Proposition?","url":"https://stock-news.laohu8.com/highlight/detail?id=2619142820","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619142820?lang=en_us&edition=fundamental","pubTime":"2026-03-14 10:26","pubTimestamp":1773455179,"startTime":"0","endTime":"0","summary":"Immunic, Inc. recently secured a key European patent for its lead asset vidofludimus calcium, aligning protection with existing U.S. coverage and potentially extending exclusivity into the 2040s for chronic inflammatory and autoimmune indications.\nThis expanded intellectual property protection materially underpins the company’s core therapeutic franchise by lengthening its runway to develop and, if approved, commercialize its main clinical asset.\nAgainst this backdrop, we’ll explore how the...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imux/immunic/news/should-extended-european-patent-protection-for-vidofludimus","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imux/immunic/news/should-extended-european-patent-protection-for-vidofludimus","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMUX","BK4587","BK4139","BK4543","BK4551","BK4528","BK4585","AI","BK4023","AIYY","BK4588"],"gpt_icon":0},{"id":"2618939742","title":"Eqs-News: Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium","url":"https://stock-news.laohu8.com/highlight/detail?id=2618939742","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618939742?lang=en_us&edition=fundamental","pubTime":"2026-03-10 18:30","pubTimestamp":1773138611,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUC7TQLZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMUX"],"gpt_icon":0},{"id":"2616341440","title":"Immunic to Join Leerink Partners Global Healthcare Conference and Stifel 2026 Virtual CNS Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2616341440","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616341440?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:30","pubTimestamp":1772537426,"startTime":"0","endTime":"0","summary":"Immunic to Join Leerink Partners Global Healthcare Conference and Stifel 2026 Virtual CNS Forum               Immunic Inc. will attend the Leerink Partners Global Healthcare Conference in Miami on Mar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL9WCLcX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","MNSH","BK4139","IMUX"],"gpt_icon":0},{"id":"2616330501","title":"Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Intellia Therapeutics (NTLA) and Immunic (IMUX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616330501","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616330501?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:31","pubTimestamp":1772458262,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascendis Pharma (ASND – Research Report), Intellia T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ascendis-pharma-asnd-intellia-therapeutics-ntla-and-immunic-imux-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ascendis-pharma-asnd-intellia-therapeutics-ntla-and-immunic-imux-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LU1861559042.SGD","BK4556","LU0320765992.SGD","LU0889565916.HKD","XBI","NTLA","BK4581","BK4585","IMUX","LU0128526141.USD","ASND","LU1861558580.USD","BK4535","HCSG","LU0029874061.USD","XLV","LABU","BK4139","LU0109394709.USD","BK4588"],"gpt_icon":0},{"id":"2616933930","title":"Immunic Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2616933930","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616933930?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:46","pubTimestamp":1772451960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMUX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 06:46 ET (11:46 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX"],"gpt_icon":0},{"id":"2616335010","title":"Immunic, Inc. : H.c. Wainwright Cuts Target Price to $5 From $8","url":"https://stock-news.laohu8.com/highlight/detail?id=2616335010","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616335010?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:24","pubTimestamp":1772450680,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nAZN4SJ4I6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMUX","BK4139"],"gpt_icon":0},{"id":"2614860609","title":"Immunic Inc. Files Initial Beneficial Ownership Statement for Director Robert Thorvald Nagel","url":"https://stock-news.laohu8.com/highlight/detail?id=2614860609","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614860609?lang=en_us&edition=fundamental","pubTime":"2026-02-28 06:01","pubTimestamp":1772229676,"startTime":"0","endTime":"0","summary":"Immunic Inc. filed an initial statement of beneficial ownership  reporting Robert Thorvald Nagel as a director. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDLZCgkz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX","BK4139"],"gpt_icon":0},{"id":"2614269120","title":"Immunic Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2614269120","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614269120?lang=en_us&edition=fundamental","pubTime":"2026-02-26 23:46","pubTimestamp":1772120763,"startTime":"0","endTime":"0","summary":"Immunic Inc reports results for the quarter ended December 31 - Earnings SummaryImmunic Inc IMUX.OQ reported a quarterly adjusted loss of 7 cents per share for the quarter ended December 31, higher th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL8N3ZM28V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"gpt_icon":0},{"id":"2614104798","title":"Immunic Q4 EPS $(0.04) Beats $(0.09) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2614104798","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614104798?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:44","pubTimestamp":1772113465,"startTime":"0","endTime":"0","summary":"Immunic (NASDAQ:IMUX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.09) by 53.49 percent. This is a 84 percent increase over losses of $(0.25) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50886741/immunic-q4-eps-0-04-beats-0-09-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX"],"gpt_icon":0},{"id":"2614403048","title":"IMUX FY 2025 Other Income (Expense) Swings to USD 5.0 million from (USD 1.0 million)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614403048","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614403048?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:30","pubTimestamp":1772105457,"startTime":"0","endTime":"0","summary":"IMUX FY 2025 Other Income (Expense) Swings to USD 5.0 million from (USD 1.0 million)               Immunic said its FY 2025 net loss was about USD 97.2 million, or USD 0.62 per basic and diluted share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL8VT4dH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMUX"],"gpt_icon":0},{"id":"2614048730","title":"Immunic Inc - Simona Skerjanec Named Interim Chairperson of Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2614048730","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614048730?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:30","pubTimestamp":1772105401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA2Y2QPC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMUX","BK4139"],"gpt_icon":0},{"id":"2614048080","title":"Immunic Inc - Raises $200 Mln in Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2614048080","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614048080?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:30","pubTimestamp":1772105401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nTUA2Y2QPC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMUX"],"gpt_icon":0},{"id":"2614482710","title":"Press Release: Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2614482710","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614482710?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:30","pubTimestamp":1772105400,"startTime":"0","endTime":"0","summary":"-- Top-Line Data from Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Expected by Year-End 2026 --. -- Raised Proceeds of $200 Million in a Private Placement, with Potential for up to an Additional $200 Million --. -- Net Proceeds Expected to Fund Completion of Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis, Initiation of Phase 3 Trial in Primary Progressive Multiple Sclerosis and Begin of Transition into a Commercial Organization --. NEW YORK, Feb. 26, 2026  /PRNewswire/ -- Immunic, Inc. , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced financial results for the year ended December 31, 2025, and provided a corporate update.Jason Tardio, President and Chief Operating Officer of Imm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875086.SGD","LU2028103732.USD","LU2089284900.SGD","LU2111349929.HKD","BK4588","LU0971096721.USD","BK4534","IE00BZ1G4Q59.USD","LU1732799900.SGD","LU1162221912.USD","LU1244550494.USD","LU0795875169.SGD","LU1548497426.USD","LU1989772923.USD","LU1791710582.SGD","LU2023251221.USD","LU0528227936.USD","LU1720051017.SGD","LU0267386448.USD","LU0882574139.USD","LU2271345857.HKD","LU2133065610.SGD","IMUX","LU0158827781.USD","LU0314104364.USD","IE00BKVL7J92.USD","LU0320765646.SGD","LU0158827948.USD","BK4504","LU0106261372.USD","LU1732800096.USD","LU1720051108.HKD","BK4516","BK4127","LU1363072403.SGD","LU0106831901.USD","LU2089283258.USD","LU0557290698.USD","LU0098860793.USD","LU2347655156.SGD","LU1791710400.SGD","LU1244550221.USD","BK4139","LU1074936037.SGD","LU0912757837.SGD","LU2357305700.SGD","LU0234570918.USD","BK4581","BK4585","LU1244550577.SGD"],"gpt_icon":0},{"id":"2613290494","title":"Immunic Inc. Announces Special Stockholders Meeting in Preliminary Proxy Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2613290494","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613290494?lang=en_us&edition=fundamental","pubTime":"2026-02-21 06:01","pubTimestamp":1771624886,"startTime":"0","endTime":"0","summary":"Immunic Inc. will hold a special meeting of stockholders in 2026 as a virtual-only meeting conducted via an online webcast. Stockholders will vote on a proposal to authorize the board of directors, within one year of stockholder approval, to amend the company’s certificate of incorporation to implement a reverse stock split of its common stock at a ratio to be set by the board within a range of 1-for-10 to 1-for-30.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 20, 2026, and is solely responsible for the information co","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL7YFBSR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX","BK4139"],"gpt_icon":0},{"id":"2612460608","title":"Immunic Raises $200 Million in Private Placement Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2612460608","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612460608?lang=en_us&edition=fundamental","pubTime":"2026-02-18 05:08","pubTimestamp":1771362484,"startTime":"0","endTime":"0","summary":"Immunic Inc. announced the closing of an oversubscribed private placement, raising $200 million upfront through the sale of 229,076,000 pre-funded warrants at $0.873 each. The transaction includes additional warrants that could bring in up to another $200 million. The proceeds will support clinical trials for multiple sclerosis and corporate operations. The securities sold are unregistered and may not be resold in the U.S. without registration or an exemption.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunic Inc. published the original content used to generate this news brief on February 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL54NYvw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMUX","BK4139"],"gpt_icon":0},{"id":"2612460361","title":"Immunic Announces Closing of Oversubscribed Private Placement Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2612460361","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612460361?lang=en_us&edition=fundamental","pubTime":"2026-02-18 05:05","pubTimestamp":1771362300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUAB0DYZ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IMUX"],"gpt_icon":0},{"id":"2611416762","title":"Why Is Immunic Stock Soaring Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2611416762","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611416762?lang=en_us&edition=fundamental","pubTime":"2026-02-14 02:55","pubTimestamp":1771008900,"startTime":"0","endTime":"0","summary":"Immunic Inc.  stock is surging on Friday with a robust session volume of 55.97 million compared to the average volume of 1.62 million, according toBenzinga Pro data.The surge follows the announcement of an oversubscribed private placement aimed at raising up to $400 million to accelerate its transformation into a commercial-stage company.The company announced a private placement of 229.08 million pre-funded warrants at $0.873 per pre-funded warrant, for upfront gross proceeds of $200 million.In addition, the company will issue warrants to purchase up to an aggregate of 229.076 million shares at an exercise price of $0.873 per share, for up to an additional $200 million in gross proceeds.The funding is expected to support the completion of the Phase 3 ENSURE trial in relapsing multiple sclerosis, with topline data expected by the end of 2026.Immunic plans to submit a New Drug Application  in the U.S. in mid-2027, with a targeted potential regulatory approval date in 2028.IMUX Price Acti","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/02/13/Defense--Biotech-Favored_0.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/02/13/Defense--Biotech-Favored_0.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/02/50622300/why-is-immunic-stock-soaring-friday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/02/50622300/why-is-immunic-stock-soaring-friday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["SMA","BK4217","BK4139","IMUX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.imux.com","stockEarnings":[{"period":"1week","weight":0.0862},{"period":"1month","weight":0.4026},{"period":"3month","weight":1.2448},{"period":"6month","weight":0.3417},{"period":"1year","weight":0.05},{"period":"ytd","weight":1.3609}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0615},{"period":"3month","weight":-0.0655},{"period":"6month","weight":-0.0253},{"period":"1year","weight":0.1345},{"period":"ytd","weight":-0.054}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 3 clinical for treatment of multiple sclerosis, including relapsing multiple sclerosis and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.061205},{"month":2,"riseRate":0.416667,"avgChangeRate":0.061188},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.021787},{"month":4,"riseRate":0.272727,"avgChangeRate":0.040308},{"month":5,"riseRate":0.090909,"avgChangeRate":-0.095662},{"month":6,"riseRate":0.583333,"avgChangeRate":0.1345},{"month":7,"riseRate":0.583333,"avgChangeRate":0.054248},{"month":8,"riseRate":0.583333,"avgChangeRate":-0.042104},{"month":9,"riseRate":0.5,"avgChangeRate":-0.073457},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.035316},{"month":11,"riseRate":0.5,"avgChangeRate":-0.001684},{"month":12,"riseRate":0.583333,"avgChangeRate":0.021046}],"exchange":"NASDAQ","name":"Immunic, Inc.","nameEN":"Immunic, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunic, Inc.(IMUX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunic, Inc.(IMUX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunic, Inc.,IMUX,Immunic, Inc.股票,Immunic, Inc.股票老虎,Immunic, Inc.股票老虎国际,Immunic, Inc.行情,Immunic, Inc.股票行情,Immunic, Inc.股价,Immunic, Inc.股市,Immunic, Inc.股票价格,Immunic, Inc.股票交易,Immunic, Inc.股票购买,Immunic, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunic, Inc.(IMUX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunic, Inc.(IMUX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction